Overview

Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use

Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the influence of genetic polymorphisms of OCTN1 and OCT2 and other possible covariates on the kinetic disposition of GAB in patients undergoing GAB chronic treatment. Thus, patients treated with GAB, for at least one week, are being investigated.
Phase:
Phase 4
Details
Lead Sponsor:
São Paulo State University
Collaborator:
University of Sao Paulo
Treatments:
Gabapentin
gamma-Aminobutyric Acid